Skip to main content

Diabetes Mellitus: Pharmacotherapy-TZDs!

 PHARMACOTHERAPY: THIAZOLIDINEDIONES

  • Commonly referred to as TZDs or Glitazones,Thiazolidinediones have established a role in T2DM Therapy.

Mechanism of Action:

  • TZDs are known to increase insulin sensitivity by stimulating peroxisome proliferator-activated receptor gamma (PPAR-g). Stimulation of PPAR-g results in a number of intracellular and extracellular changes including increased insulin sensitivity and decreased plasma fatty acid levels.

Pharmacokinetics:

  • The onset of TZDs is delayed for several weeks and require up ton 12 weeks before maximum effects are observed.

Therapy:

  • As monotherapy, TZDs reduce FPG levels by around 60-70mg/dL and the effect of A1c is up to 1.5% reduction.


Clinical Uses:

  • Pioglitazone and Rosiglitazone increases HDL. Pioglitazone increases HDL by 5.2mg/dL Rosiglitazone increases HDL levels by 2-4mg/dL.
  • Pioglitazone decreases serum Triglycerides by an average of 51.9mg/dL. Rosiglitazone increases serum triglycerides.
  • Pioglitazone increases LDL levels by 12.3 mg/dL. Rosiglitazone increases LDL levels by 21.3mg/dL.


Adverse Effects:

  1. Fluid retention
  2. Edema
  3. Hepatotoxicity
  4. It is known that blood volume increases approximately 10% with these agents resulting in approximately 4-5% patients developing edema.


Contraindications:

These drugs are contraindicated in pt. with;

  • in situations in which increased fluid retention is detrimental such as heart failure.
  • Insulin therapy
  • Patients with a baseline alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal.
  • Increased rate of upper and lower limb fractures tends to occur with TZD therapy, hence patients with baseline fracture risk are contraindicated to receive TZDs.
  • Premenopausal women may begin to ovulate on TZD therapy and therefore counselling should be provided to all women capable to begin pregnant regarding this.
  • TZD is pregnancy category C drug, so proper precautions to avoid pregnancy should be used.
  •   In June 2011, the FDA alerted healthcare providers and patients that pioglitazone was found to be associated with an increased risk of bladder cancer after 1 year of therapy in ongoing epidemiological study.
  • As 2007 meta-analysis conducted by Nissen and colleagues, reported that non-significant increase in myocardial infarction with Rosiglitazone compared with other oral agents.
  • A subsequent prospective study found Rosiglitazone use to be associated with a non-significant increase in Myocardial infarction risk and non-significant reduction in stroke, but a trend towards increased cardiovascular risk in those patients with Ischemic stroke.
  • In May 2011, the FDA chose to restrict access and distribution of Rosiglitazone. It is currently only available through the Avandia-Rosiglitazone Medicines access Program for patients currently benefiting from the drug and in those who cannot achieve adequate disease management with other agents or who are not willing to use pioglitazone-containing medications after counselling with their healthcare provider.



Labels

Labels:

Comments

Post a Comment

Popular posts from this blog

Drug-Induced Ototoxicity!

 DRUG-INDUCED OTOTOXICITY What is drug Induced Ototoxicity? Drug-Induced ototoxicity can affect hearing (auditory or cochlear function0, balance (vestibular function) depending on the drug. Drugs of almost every class have been reported to produce tinnitus (sounds in ear), as have placebos. The following agents are associated with measurable changes in hearing or vestibular defect when administered systemically. 1. AMINOGLYCOSIDES: Aminoglycosides antibiotics can cause cochlear or vestibular toxicities. Cochlear toxicity: occurs as progressive hear loss, starting with highest tones and advancing to lower tones. Thus, considerable damage can occur before the patient recognizes it. S ymptoms of Vestibular damage : include;  Dizziness Vertigo Ataxia Both forms of ototoxicity are bilateral and potentially reversible, but permanent damage is common and can progress even after discontinuation of aminoglycosides. Clinically detectable ototoxicity in as many as 5% patients. Most amin...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-5...
Post a Comment
Read more

Myocardial Infarction- Etiology, Pathogenesis, Clinical Diagnosis and Management!

MYOCARDIAL INFARCTION Definition: Myocardial Infarction is defined as " a diseased condition which is caused by reduced blood flow to the coronary artery due to atherosclerosis and occlusion of artery by embolus or thrombus." Myocardial Infarction (or Heart attack) is the irreversible damage of myocardial tissue due to prolonged ischemia or hypoxia. Universally accepted definition of MI:  Evidence of myocardial necrosis in consistent with the myocardial ischemia, in which case any of the following meets the diagnosis of Myocardial Infarction. Evidence rises and/or fall of cardiac biomarkers (preferably troponin). ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block) Development of pathological Q waves. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Etiology: Tobacco smoking Diabetes Mellitus Age Hypertension Obesity Gender Stress Drug abuse Alcohol consumption Family history of ischemic heart dise...
Post a Comment
Read more